The present invention relates to compounds capable of acting as androgen receptor antagonists, pharmaceutical formulations containing the same, and methods of use thereof. Such uses include, but are not limited to, use as antitumor agents, particularly for the treatment of cancers such as colon, skin and prostate cancer and to induce androgen receptor antagonist activity in a subject afflicted with an androgen-related affliction. Examples of androgen-related afflictions include, but are not limited to, baldness, hirsutism, behavioral disorders, acne, and uninhibited spermatogenesis wherein inhibition of spermatogenesis is so desired.

Claims

13 · 5 independent · depth 2

13 granted claims

›1.independentA compound having the following structure:

›2.independentA pharmaceutical formulation comprising a compound of

›3.independentA method of treating an androgen related cancer, comprising administering to a subject in need thereof a treatment effective amount of a compound havi…+2

›4.independentA method of inducing androgen receptor antagonist activity, said method comprising contacting a cell with an androgen receptor antagonist effective am…+3

›5.independentA method of inducing androgen receptor antagonist activity in a subject afflicted with an androgen-related affliction, said method comprising administ…+3

Classifications

5 codes

IPC · International Patent Classification

Section A — Human necessities

A01N35/00

Section C — Chemistry; metallurgy

C07C49/00

USPC · US Patent Classification

514/705568/325514/679

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

1.6 y

594 days filing → grant

Office actions

after a restriction

Responses

1 RCE

Examiner

Yate' K Cutliff

art unit —

Law firm

Law firm · Log in to unlock

Citations: 52 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20080146660 A1	19 Jun 2008

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.